The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

The fuel gauge showed just a tiny amount of hydrogen in the vehicle’s tank, and someone on the sales staff at Roseville ...

Electric cars have soared in popularity in the wake of high gasoline prices. While improvements in vehicle battery technology ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

Hydrogen-powered vehicles are the new kids on the block and they come with some advantages and disadvantages when compared to ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before ...

Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

This cancer-patient dad of three young kids is grateful for a "sci-fi" blood treatment advanced by Vanderbilt and oncologist Dr. Olalekan Oluwole.

A cornerstone of the immune system is its ability to maintain self-tolerance. This defense network orchestrates effector responses against pathogenic ...